Local pulmonary administration of factor VIIa (rFVIIa) in massive pulmonary haemorrhage in post-operative cardiac infant.
Hussam K HamadahMohamed S KabbaniPublished in: Cardiology in the young (2022)
Diffuse pulmonary haemorrhage is an ominous condition that has a high paediatric mortality rate. Recombinant activated factor VIIa (rFVIIa) is a powerful haemostatic agent which has been used intravenously in life-threatening haemorrhage in variety of conditions in which conventional medical or surgical therapy are unsuccessful. We report off-label successful use of endotracheal rFVIIa for massive life-threatening respiratory haemorrhage following aspiration and cardiopulmonary resuscitation in a 3-month-old infant who was anticoagulated with enoxaparin following corrective cardiac surgery with other comorbidities. Off-label administration of endotracheal rFVIIa permitted rapid safe control of massive pulmonary haemorrhage and prevented further detrimental decline in respiratory function with satisfactory outcome.
Keyphrases
- quantum dots
- pulmonary hypertension
- sensitive detection
- cardiopulmonary resuscitation
- cardiac arrest
- cardiac surgery
- healthcare
- emergency department
- acute kidney injury
- venous thromboembolism
- stem cells
- cardiovascular disease
- type diabetes
- cardiovascular events
- risk factors
- mesenchymal stem cells
- low grade
- respiratory tract
- heart failure
- bone marrow
- cell therapy
- cell free